{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-153427","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.025174+00:00","generated_at":"2026-05-18T10:18:32.854852+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jade Biosciences appoints Brad Dahms as CFO, enters manufacturing agreement with Patheon for JADE101","bullets":["Brad Dahms appointed CFO effective July 14, 2025; base salary $500K, target bonus 40%, option for 526,000 shares vesting over 4 years.","Patheon MSA covers cGMP manufacturing for JADE101 and future programs; initial 5-year term with auto-renewal; non-cancellable fees per project.","Dahms previously CFO of IDRx (sold to GSK), Theseus (sold to Concentra), and Selecta; brings 15 years biotech and investment banking experience.","Company advancing JADE101 into clinic this year for IgA nephropathy; recent Nasdaq listing and private financing provide momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-153427","json":"https://secwatch.observer/filing/0001193125-25-153427.json","markdown":"https://secwatch.observer/filing/0001193125-25-153427.md","text":"https://secwatch.observer/filing/0001193125-25-153427.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525153427/0001193125-25-153427-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000119312525153427/d71010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:18:32.854852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}